Clinical Trial Update: Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1/1b trial of olutasidenib and ziftomenib for NPM1 and IDH1 co-mutated acute myeloid leukemia is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Olutasidenib (olutasidenib)
• Ziftomenib (ziftomenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: NOT_YET_RECRUITING